REFERENCES
1. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin,molecular class, and effects on patient prognosis. Gastroenterology 2017;152:745-61.
2. Yang F, Ma L, Yang Y, Liu W, Zhao J, et al. Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. Front Oncol 2019;21;9:370.
3. Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol 2017:302-9.
4. Liu W, Wu J, Du Y, Cao G. Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis. Curr Oncol 2016;23:e49-56.
5. Deng Y, Du Y, Zhang Q, Han X, Cao G. Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and hepatocellular carcinoma. Cancer Lett 2014;343:161-71.
6. Cao G. Cancer Evo-Dev, a novel hypothesis derived from studies on hepatitis B virus-induced carcinogenesis. Hepatoma Res 2017;3:241-59.
7. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013;45:970-6.
8. Wang D, Li X, Li J, Lu Y, Zhao S, et al. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression. Gut 2019. Epub ahead of print. doi: 10.1136/gutjnl-2018-317601
9. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-8.
10. Liu W, Wu J, Yang F, Ma L, Ni C, et al. Genetic polymorphisms predisposing the interleukin-6-induced APOBEC3B-UNG imbalance increase HCC risk via promoting the generation of APOBEC-signature HBV mutations. Clin Cancer Res 2019; doi: 10.1158/1078-0432.CCR-18-3083.